AOP spins off majority stake in cancer vaccine biotech; Ambrx strikes China collaboration deal;

@FierceBiotech: Analysis: Big Pharma R&D demonstrates a woeful lack of innovation. News | Follow @FierceBiotech

 @JohnCFierce: AOP spins off its 80% stake in Activartis (cancer vaccines) after Elan shareholders reject takeover bid. Release | Follow @JohnCFierce

@RyanMFierce: In $247M Transition deal, Eli Lilly is reeling in a diabetes drug candidate that it had spun off (sort of): Yesterday's item | Follow @RyanMFierce

> Soon after Elan's ($ELN) shareholders nixed a series of deals, including the acquisition of Vienna-based AOP Orphan Pharmaceuticals, the biotech announced that it is spinning off its 80% ownership in Activartis--a cancer vaccine developer--to a group of private investors. Release

> Ambrx and China's Zhejiang Medicine Co. will collaborate on the development and commercialization of ARX788, Ambrx's most advanced antibody drug conjugate targeting HER2-positive breast cancer. Release

Pharma News

@FiercePharma: Valeant to sell $2B worth of stock to finance Bausch + Lomb buyout, plus issue $7.5B in debt. More | Follow @FiercePharma

@EricPFierce: India's Roselabs sees lots of upside in prefilled syringes for the Indian market. Story | Follow @EricPFierce

@CarlyHFierce: Bristol-Myers makes another emerging markets move with Simcere partnership in China. Yesterday's story | Follow @CarlyHFierce

> Who wins after SCOTUS pay-for-delay decision? Lawyers. More

> Want a raise, pharma reps? Get into biotech sales instead. Story

Medical Device News

@FierceMedDev: Exact raising $63.7M on rocky road to FDA approval. News | Follow @FierceMedDev

@DamianFierce: Medtronic's Infuse no better than graft procedure but more dangerous, according to independent reviews. More | Follow @DamianFierce

@MichaelGFierce: Check out our new FierceBiotech LinkedIn page... and sign up to join the discussion! LinkedIn group page | Follow @MichaelGFierce

> Boston Scientific targets FDA with brain-stim trial. Story

> Endologix endures FDA deadly warning over recall. Item

> Globus owes $16M in J&J patent suit. Report

Biotech Research News

 @EmilyMFierce: Have you joined the @FierceBiotech LinkedIn group yet? Connect with biotech colleagues and join the discussion: Join now | Follow @EmilyMFierce

> Breast cancer cell growth thwarted by osteoporosis drug in preclinical studies. Report

> New genetic mutations found in families with early-onset Alzheimer's. Item

> Inovio says H7N9 bird flu vaccine effective in mice. Story

> Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. More

Pharma Manufacturing News

> French plant part of proposed GSK, Aspen deal. Item

> Roselabs taps growth of prefilled syringe in India. Report

> City forecloses on Indiana insulin plant it helped fund. Article

> Eisai adding packaging facility to U.K. plant. More

And Finally… Investigators say that a low-fat, low-carb diet can reduce the level of beta-amyloid peptides, perhaps reducing the risk of Alzheimer's. Researchers emphasized, though, that they have no firm idea yet if this kind of diet would have a significant impact on the risk of developing the memory-robbing disease that now afflicts millions. Story